Jiang X - Search Results

1

A Hybrid Nanoadjuvant Simultaneously Depresses PD-L1/TGF-β1 and Activates cGAS-STING Pathway to Overcome Radio-Immunotherapy Resistance.

Yi L, Jiang X, Zhou Z, Xiong W, Xue F, Liu Y, Xu H, Fan B, Li Y, Shen J. Yi L, et al. Among authors: jiang x. Adv Mater. 2024 Apr;36(15):e2304328. doi: 10.1002/adma.202304328. Epub 2024 Jan 22. Adv Mater. 2024. PMID: 38229577

2

Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.

Xiong W, Qi L, Jiang N, Zhao Q, Chen L, Jiang X, Li Y, Zhou Z, Shen J. Xiong W, et al. Among authors: jiang n, jiang x. ACS Appl Mater Interfaces. 2021 Feb 24;13(7):8026-8041. doi: 10.1021/acsami.0c21743. Epub 2021 Feb 12. ACS Appl Mater Interfaces. 2021. PMID: 33577301

3

Effective tumor vessel barrier disruption mediated by perfluoro-N-(4-methylcyclohexyl) piperidine nanoparticles to enhance the efficacy of photodynamic therapy.

Xiong W , Qi L , Si D , Jiang X , Liu Y , Zheng C , Li Y , Shen J , Zhou Z . Xiong W , et al. Among authors: jiang x. Nanoscale. 2021 Aug 21;13(31):13473-13486. doi: 10.1039/d1nr02880d. Epub 2021 Jul 30. Nanoscale. 2021. PMID: 34477752

4

Tumor Selective Metabolic Reprogramming as a Prospective PD-L1 Depression Strategy to Reactivate Immunotherapy.

Liu Y, Zhou Z, Hou J, Xiong W, Kim H, Chen J, Zheng C, Jiang X, Yoon J, Shen J. Liu Y, et al. Among authors: jiang x. Adv Mater. 2022 Oct;34(41):e2206121. doi: 10.1002/adma.202206121. Epub 2022 Sep 7. Adv Mater. 2022. PMID: 36017886

5

Metformin modified chitosan as a multi-functional adjuvant to enhance cisplatin-based tumor chemotherapy efficacy.

Zhou Z, Liu Y, Jiang X, Zheng C, Luo W, Xiang X, Qi X, Shen J. Zhou Z, et al. Among authors: jiang x. Int J Biol Macromol. 2023 Jan 1;224:797-809. doi: 10.1016/j.ijbiomac.2022.10.167. Epub 2022 Oct 23. Int J Biol Macromol. 2023. PMID: 36283555

6

Metabolic reprogramming mediated PD-L1 depression and hypoxia reversion to reactivate tumor therapy.

Zhou Z, Liu Y, Song W, Jiang X, Deng Z, Xiong W, Shen J. Zhou Z, et al. Among authors: jiang x. J Control Release. 2022 Dec;352:793-812. doi: 10.1016/j.jconrel.2022.11.004. Epub 2022 Nov 11. J Control Release. 2022. PMID: 36343761

7

An in situ protonation-activated supramolecular self-assembly for selective suppression of tumor growth.

Wu X, Liu M, Niu J, Liu Q, Jiang X, Zheng Y, Qian Y, Zhang YM, Shen J, Liu Y. Wu X, et al. Among authors: jiang x. Chem Sci. 2023 Jan 17;14(7):1724-1731. doi: 10.1039/d2sc05652f. eCollection 2023 Feb 15. Chem Sci. 2023. PMID: 36819851 Free PMC article.

8

Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review.

Zhou Z, Wang H, Li J, Jiang X, Li Z, Shen J. Zhou Z, et al. Among authors: jiang x. Int J Biol Macromol. 2024 Jan;254(Pt 2):127911. doi: 10.1016/j.ijbiomac.2023.127911. Epub 2023 Nov 7. Int J Biol Macromol. 2024. PMID: 37939766 Review.

9

Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.

Jiang X, Yi L, Li C, Wang H, Xiong W, Li Y, Zhou Z, Shen J. Jiang X, et al. ACS Nano. 2024 Jan 30;18(4):3331-3348. doi: 10.1021/acsnano.3c10117. Epub 2024 Jan 16. ACS Nano. 2024. PMID: 38227812

10

Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced-Pulmonary Fibrosis.

Zhou Z, Jiang X, Yi L, Li C, Wang H, Xiong W, Li Z, Shen J. Zhou Z, et al. Among authors: jiang x. Adv Sci (Weinh). 2024 Jul;11(26):e2401394. doi: 10.1002/advs.202401394. Epub 2024 May 7. Adv Sci (Weinh). 2024. PMID: 38715382 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29,796 results

Search Page

Filters